

Marc Thibonnier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4572024/publications.pdf>

Version: 2024-02-01

37
papers

1,964
citations

331670

21
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

1402
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Vascular Endothelial Cells Express Oxytocin Receptors*. Endocrinology, 1999, 140, 1301-1309.	2.8	281
2	Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Letters, 1994, 356, 215-220.	2.8	175
3	Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology, 2003, 61, 8-14.	1.0	136
4	Signal transduction of V1-vascular vasopressin receptors. Regulatory Peptides, 1992, 38, 1-11.	1.9	127
5	Molecular Pharmacology of Human Vasopressin Receptors. Advances in Experimental Medicine and Biology, 1998, 449, 251-276.	1.6	117
6	The Human V ₃ Pituitary Vasopressin Receptor: Ligand Binding Profile and Density-Dependent Signaling Pathways ¹ . Endocrinology, 1997, 138, 4109-4122.	2.8	115
7	Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Progress in Brain Research, 1999, 119, 147-161.	1.4	96
8	Multiple Signaling Pathways of V1-Vascular Vasopressin Receptors of A75rCells*. Endocrinology, 1991, 129, 2845-2856.	2.8	82
9	VARDENAFIL IMPROVED PATIENT SATISFACTION WITH ERECTILE HARDNESS, ORGASMIC FUNCTION AND SEXUAL EXPERIENCE IN MEN WITH ERECTILE DYSFUNCTION FOLLOWING NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 2067-2071.	0.4	82
10	Structure, Sequence, Expression, and Chromosomal Localization of the Human V1a Vasopressin Receptor Gene. Genomics, 1996, 31, 327-334.	2.9	74
11	Arrestin Binding to Calmodulin: A Direct Interaction Between Two Ubiquitous Signaling Proteins. Journal of Molecular Biology, 2006, 364, 955-963.	4.2	72
12	Study of V1-vascular Vasopressin Receptor Gene Microsatellite Polymorphisms in Human Essential Hypertension. Journal of Molecular and Cellular Cardiology, 2000, 32, 557-564.	1.9	71
13	Mapping the Binding Site of Six Nonpeptide Antagonists to the Human V ₂ -Renal Vasopressin Receptor. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 564-571.	2.5	54
14	Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension. American Journal of Cardiology, 1982, 49, 1447-1452.	1.6	45
15	Vasopressin receptor antagonists in heart failure. Current Opinion in Pharmacology, 2003, 3, 683-687.	3.5	42
16	Vardenafil Improves Patient Satisfaction with Erection Hardness, Orgasmic Function, and Overall Sexual Experience, While Improving Quality of Life in Men with Erectile Dysfunction. Journal of Sexual Medicine, 2004, 1, 185-192.	0.6	40
17	Cytoplasmic and nuclear signaling pathways of V1-vascular vasopressin receptors. Regulatory Peptides, 1993, 45, 79-84.	1.9	36
18	Improved Diagnosis of Unilateral Renal Artery Lesions After Captopril Administration. JAMA - Journal of the American Medical Association, 1984, 251, 56.	7.4	33

#	ARTICLE	IF	CITATIONS
19	Erection Quality Scale: Initial scale development and validation. <i>Urology</i> , 2004, 64, 351-356.	1.0	32
20	Vardenafil provides reliable efficacy over time in men with erectile dysfunction. <i>Urology</i> , 2004, 64, 1187-1195.	1.0	31
21	The Human Platelet Vasopressin Receptor and Its Intracellular Messengers. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 10, 24-29.	1.9	26
22	Abnormal regulation of antidiuretic hormone in idiopathic edema. <i>American Journal of Medicine</i> , 1979, 67, 67-73.	1.5	22
23	Metabolic and energetic benefits of microRNA-22 inhibition. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001478.	2.8	22
24	The genetics of hypertension. <i>Current Opinion in Genetics and Development</i> , 1995, 5, 362-370.	3.3	20
25	Molecular Dynamics Study of the Hybridization between RNA and Modified Oligonucleotides. <i>Journal of Chemical Theory and Computation</i> , 2019, 15, 6422-6432.	5.3	17
26	Metabolic Benefits of MicroRNA-22 Inhibition. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 104-116.	3.6	17
27	Genetics of vasopressin receptors. <i>Current Hypertension Reports</i> , 2004, 6, 21-26.	3.5	16
28	Role of the human V ₁ vasopressin receptor COOH terminus in internalization and mitogenic signal transduction. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 281, E81-E92.	3.5	15
29	Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 825-834.	4.1	14
30	Osmoregulation and renal effects of vasopressin in normal and mildly hypertensive subjects. <i>Kidney International</i> , 1984, 25, 411-415.	5.2	13
31	Solubilization of human platelet vasopressin receptors. <i>Life Sciences</i> , 1987, 40, 439-445.	4.3	11
32	A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2005, 61, 341-345.	0.7	9
33	Binding characteristics of atrial natriuretic factor and the production of cyclic GMP in kidneys of DAHL salt-sensitive and salt-resistant rats. <i>Biochemical and Biophysical Research Communications</i> , 1987, 144, 1076-1083.	2.1	7
34	Soluble Mimics of the Cytoplasmic Face of the Human V1-Vascular Vasopressin Receptor Bind Arrestin2 and Calmodulin. <i>Molecular Pharmacology</i> , 2006, 70, 249-258.	2.3	7
35	Dynamic study of antidiuretic hormone during benign mineralocorticoid and metacorticoid hypertension. <i>European Journal of Endocrinology</i> , 1980, 95, 444-453.	3.7	5
36	Acute Inhibition of the Renin-Angiotensin System. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S82-S85.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Effects of a short-term cold exposure on circulating microRNAs and metabolic parameters in healthy adult subjects. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 548-562.	3.6	1